Discovery & History
How a young blood serum experiment at UCSF led to the discovery of a tiny molecule that modulates 32% of human genes
The Molecule That Rewrites Aging
In 1973, a doctoral student at the University of California, San Francisco made a discovery that would take four decades to fully appreciate. By comparing old liver tissue with young blood serum, Loren Pickart found a tiny molecule -- just three amino acids bound to copper -- that could make old cells behave like young ones again.
That molecule is GHK-Cu. Today we know it modulates over 4,000 human genes, reverses disease gene signatures, and plays a role in everything from wound healing to hair growth. This is its story.
Pickart's Discovery
Loren Pickart (1938-2023) was studying protein synthesis in human liver tissue for his doctoral dissertation at UCSF. His research question was simple but profound: why does liver tissue from older people behave differently than liver tissue from younger people?
Pickart compared liver tissue from two groups of donors. Tissue from patients aged 60-80 showed elevated fibrinogen levels -- a protein linked to inflammation and cardiovascular disease. Younger tissue (age 20-25) had normal, healthy levels.
But the interesting part wasn't the difference itself. It was what happened next.
Young Serum, Old Cells
Pickart's pivotal experiment was elegantly simple. He took old liver cells (age 60-80) and bathed them in blood serum from young donors (age 20-25). The results were remarkable.
The old cells began functioning nearly identically to young liver tissue. Fibrinogen synthesis patterns reverted to youthful profiles. It was as if the clock had been turned back on the aging cells.
Something in the young blood serum was actively reprogramming the old cells. Pickart set out to isolate this rejuvenating factor.
Identifying the Molecule
Pickart traced the rejuvenating activity to a small peptide bound to the albumin fraction of human plasma. Through biochemical fractionation, he isolated the active component.
The molecule turned out to be remarkably small: just three amino acids -- glycine, L-histidine, and L-lysine -- with a strong affinity for copper(II) ions. This tripeptide-copper complex was designated GHK-Cu (glycyl-L-histidyl-L-lysine copper).
In 1977, David Schlesinger at Harvard confirmed the amino acid sequence. By 1984, Perkins et al. had solved the complete crystal structure using X-ray crystallography, revealing a square-planar coordination geometry where copper sits at the center of the peptide.
The molecular weight of the GHK-Cu complex is approximately 340-403 Da depending on the salt form -- small enough to potentially penetrate skin.
Key Milestones
From a doctoral thesis to NASDAQ, from cosmetic creams to genome-wide studies -- follow the 50-year journey of GHK-Cu research.
A key turning point came in 1994 when Lane et al. at the Journal of Cell Biology identified GHK as a fragment released from the SPARC protein (secreted protein acidic and rich in cysteine). This linked GHK-Cu to angiogenesis -- the growth of new blood vessels -- and expanded its known biological significance beyond liver cells.
The modern era of GHK-Cu research was launched in 2010 when researchers used the Broad Institute's Connectivity Map to screen 1,309 bioactive compounds. GHK emerged as the most active substance for reversing the gene expression signature of metastatic colon cancer. This finding, published by Hong et al. in Clinical and Experimental Metastasis, sparked renewed scientific interest.
Why It Matters Today
GHK-Cu is one of the most studied copper peptides in existence, with over 60 peer-reviewed publications spanning wound healing, dermatology, gene expression, and regenerative medicine.
The 2014 landmark study by Pickart, Vasquez-Soltero, and Margolina documented what makes GHK-Cu truly exceptional: it modulates 32.1% of human genes -- approximately 4,000 out of 13,424 analyzed. Of those affected, about 59% are upregulated and 41% suppressed.
But GHK-Cu is not just a laboratory curiosity. It exists naturally in your blood plasma right now. Young adults (age 20-25) have about 200 ng/mL. By age 60-80, that drops to about 80 ng/mL -- a 60% decline that coincides with decreased regenerative capacity.
In the units ahead, you'll learn exactly how this tiny tripeptide works: the copper delivery system, collagen synthesis, anti-inflammatory cascades, gene expression patterns, and practical applications from skincare to wound healing. Each claim will be traced back to its primary research source.
Knowledge Check
Test what you've learned about the discovery and history of GHK-Cu.
Practice Exercises
Reinforce your understanding with interactive exercises.